| Name | Title | Contact Details |
|---|
Lindsey Management Co., Inc. (LMC) is a leading property management firm located in Fayetteville, Arkansas. Founded in 1985, it has become the largest company in Arkansas specializing in multi-family housing and has expanded its services into neighboring states such as Alabama, Kansas, Mississippi, Missouri, and Oklahoma. LMC provides a wide range of property management services, primarily focusing on multi-family housing. The company manages over 140 apartment communities, totaling more than 32,000 apartments and executive suites. Additionally, LMC oversees numerous golf courses, including five Par 3 courses, five executive courses, thirteen regular courses, and sixteen 18-hole courses across Arkansas and surrounding states. Its services include leasing, maintenance, and customer support for both residential and recreational properties.
The first youth-powered consulting and market research agency. Join us in building confidence, fostering skills, and shaping brighter futures for all.
In 1990, Nitro Snowboards was founded by Thomas Delago and Sepp Ardelt in Seattle, Washington. Over the last 25 years Nitro has helped grow the sport of snowboarding through its groundbreaking product development, marketing, movies, grass roots events, and global team of world class snowboarders. Today Nitro has grown its product to offer all the essentials needed for having a good time snowboarding and traveling. Nitro´s headquarters are divided all over the world from the Mountains of Oberammergau, to the worlds best snow in Salt Lake City, UT, to the creative beaches of California, all the way up to the Northwest snowboarding destination of Vancouver, British Colombia. For more information visit us at http://www.nitrosnowboards.com or @NITROUSA on Instagram
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.